• Clinical experience with Septolete plus products in the treatment of sore throat 
To content

Clinical experience with Septolete plus products in the treatment of sore throat 


Clinical experience with Septolete plus products in the treatment of sore throat 

Kosir Р. 

A sore throat is a common complaint among children, adolescents and adults. It refers to a painful sensation localised to the pharynx and surrounding anatomy and can be a symptom of a disease process not directly linked to the pharynx (e.g. cold or flu). The treatment of sore throat depends upon the cause. Due to the predominantly viral cause, antibiotics have only a marginal benefit as they do not improve throat pain and are thus not recommended. An alternative to systemic antibiotic therapy in such cases is the use of oral antiseptics, which are often combined with local anesthetics to relieve pain and thus alleviate subjective discomfort. Septolete plus products contain a broad-spectrum antiseptic, cetylpyridinium chloride (CPC), and the local anesthetic benzocaine. In clinical studies Septolete plus has demonstrated high efficacy and good tolerability in the treatment of sore throat. The analgesic effect of Septolete plus lozenges started in fifteen minutes and lasted for two to three hours. Complete healing or improvement of the signs and symptoms of the disease was observed in 90–100% of the patients treated with Septolete plus lozenges and 87.5% of the patients treated with Septolete plus oromucosal spray. Secondary infections occurred in not more than 3.8% of the patients treated with lozenges. Additionally, a considerable reduction in the microorganism count was demonstrated for Septolete plus lozenges. 

Key words: pharyngitis, antiseptics, local anesthetics, cetylpyridinium chloride, benzocaine. 


1. Bisino A. 2011. Acute pharyngitis. The New England Journal of Medicine. 344; 3: 205—11. http://dx.doi.org/10.1056/NEJM200101183440308; PMid:11172144

2. Hannaford PC, Simpson JA, Bisset AF, Davis A, McKerrow W, Mills R. 2005. The prevalence of ear, nose and throat problems in the community: results from a national cross-sectional postal survey in Scotland. Fam Pract. 22: 227—33. http://dx.doi.org/10.1093/fampra/cmi004; PMid:15772117

3. Clements AD. 1999. Pharyngitis, laryngitis and epiglottitis. In: Cohen J, Powderly WG. Infectious diseases. Vol 1. London: Harcourt Publishers Ltd: 341—7.

4. Hughes W. 1992. Candidiasis. In: Feign RD, Cherry DJ. Textbook of pediatric infectious diseases. Vol 2. Philadelphia: W. B. Saunders Company: 1907—11.

5. Addey D. 2012. Incidence, causes, severity and treatment of throat discomfort: a four-region online questionnaire survey. BMC Ear Nose Throat Disord. http://dx.doi.org/10.1186/1472-6815-12-9; PMid:22883470 PMCid:PMC3489867

6. Wunderer H. 1986. Mund- und Rachentherapeutika. DAZ. 126(42): 2281—92.

7. Akpan A. 2002. Oral candidiasis. Postgrad Med J. 78: 455—9. http://dx.doi.org/10.1136/pmj.78.922.455; PMid:12185216 PMCid:PMC1742467

8. Little PS, Wiliamson I. 1994. Contraversis in management: Are antibiotics appropriate for sore throats? Costs outweigh the benefits. BMJ. 309(6960): 1010—1. http://dx.doi.org/10.1136/bmj.309.6960.1010; PMid:7950695 PMCid:PMC2541287

9. Little PS, Wiliamson I, Warner G et al. 1981. Open randomised trial of prescribing strategies in managing sore throat. Practitioner. 225(1352): 234—9.

10. Konschal U. 1977. Antiseptische Lokaltherapeutika als eigenstandige Therapie HNO-arztlich gesehen. Therapiewoche. 27: 7732—9.

11. Meier E. 1990. Schluckbeschwerden, Halsschmerzen, Heiserkeit. Apotheker Journal. 12: 26–32.

12. Weber R. 1987. Mund- und Rachentherapeutika. PTA heute. 1(4): 108—11.

13. Sweetman S. 2008. Martindale: The Complete Drug Reference: Cetylpyridinium chloride. London: Pharmaceutical Press. Electronic version.

14. Kramer A. 1990. Hagers Handbuch der Pharmazeutischen Praxis, 5 Aufl. Bd7 Springer-Verlag, Berlin-Heidelberg.

15. Merianos JJ. 1991. Quaternary ammonium antimicrobial compounds. In: Block SS: Disinfection, Sterilisation and Preservation. 4th ed. Philadelphia, London: Lea & Febiger: 225—55.

16. Drugdex Drug Evaluations: Benzocaine. Micromedex® Healthcare Series: MICROMEDEX, Inc., Englewood, Colorado, Vol 138. Expires 12/2008.

17. Strichartz G. 1976. Molecular mechanism of nerve block by local anesthetics. Anesthesiology. 15 (1): 421—41. http://dx.doi.org/10.1097/00000542-197610000-00012

18. Bulc M. 2003. Final report. Monitoring of efficacy and safety of the medicinal product Septolete plus in patients with pharyngeal pain. Data on file. Krka, d. d., Novo mesto, Slovenia.

19. Рязанцев СВ, Тимчук ЛE. 2005. Итоговый отчет. Исследование эффективности и безопасности продукта «Септолете плюс» у пациентов с ангиной. Россия, Санкт-Петербург. Data on file. KPKA, d. d., Novo mesto, Slovenia.

20. Final report. Post-authorisation non-interventional study of the efficacy and safety of the medicinal product Neoseptolete with anesthetic effect, orm. pas., Czech Republic. Data on file. Krka, d. d., Novo mesto, Slovenia, 2007.

21. Zabolotny DI. 2007. Final report. Open-labeled non-comparative uncontrolled study of the efficacy and safety of Septolete plus in patients with a sore throat, Ukraine. Data on file. Krka, d. d., Novo mesto, Slovenia.

22. Заболотний ДИ и др. 2007. Лечение хронического фарингита в фазе обострения: клинико-иммунологические и микробиологические аспекты. Медична газета «Здоров'я України». 19(176): 1–3.

23. Final report. A comparative study of the efficacy and safety of Septolete plus oromucosal spray 1.5 mg + 0.3 mg/dose (cetylpiridinium chloride/benzocaine) in subjects with sore throat associated with upper respiratory tract infections, including tonsillopharyngitis: a comparison with the reference product TheraFlu LAR spray; Phase III study. Data on file. Krka, d. d., Novo mesto, Slovenia, 2013.